

Edison Investment Research Ltd. Initiates Coverage of SynAct Pharma

SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, is now being covered by UK based Edison Investment Research Ltd.

"We are happy to be working with Edison on providing equity research coverage. The team at Edison is highly regarded and professionally driving equity coverage in the pharma and biotech industry," said Jeppe Øvelsen, Chief Executive Officer of SynAct Pharma.

Please see the Initiation Report on <https://www.edisongroup.com/research/differentiated-inflammation-resolution-approach/BM-2174/>

For further information, please contact:

Jeppe Øvelsen

CEO, SynAct Pharma AB

Phone: + 45 2844 7567

E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: <https://synactpharma.com/>.

Attachments

[Edison Investment Research Ltd. Initiates Coverage of SynAct Pharma](#)